Myriant Appoints Susan Hager as Senior Vice President of Corporate Communications and Government Affairs

QUINCY, Mass.--()--Myriant Corporation (Myriant), an industrial biotech company focused on the production of bio-based chemicals that substitute for petroleum-based chemicals, announced today the appointment of Susan Hager as Senior Vice President of Corporate Communications and Government Affairs. Ms. Hager will lead the Company’s strategic communications efforts and government-related activities and will report directly to Stephen J. Gatto, Chairman and Chief Executive Officer.

“Susan has a superior reputation in the industrial biotechnology industry for developing and executing highly strategic, results-driven communications programs that advance business objectives,” said Stephen Gatto. “Susan brings the right combination of energy, creativity and entrepreneurial drive that makes her an ideal addition to Myriant’s leadership team.”

Ms. Hager has more than 17 years of experience of developing results-driven communications campaigns for industrial biotech and life science companies in both the private and public sectors. Her expertise includes corporate communications, investor and media relations, and government affairs in support of complex product marketing and commercialization initiatives.

Most recently, Ms. Hager was Vice President of Corporate Communications and Government Affairs for Qteros. Ms. Hager served previously as a Director in the Corporate Communications and Investor Relations practice for WCG, a global communications agency, where she created and led the implementation and execution of integrated, strategic communications programs for the firm's clients in the United States and Europe. Ms. Hager has also served as Vice President, Corporate Communications and Investor Relations for Targanta Therapeutics (sold to The Medicines Company), as well as Vice President, Corporate Communications, Investor Relations and Corporate Development for Coley Pharmaceutical Group (sold to Pfizer Inc). She has also held global marketing and communications roles with Bayer HealthCare LLC. Ms. Hager received a BS in Biology and an MBA from Northeastern University.

About Myriant

Myriant utilizes proprietary technology to provide innovative, performance-based renewable chemicals utilizing low-cost sugars. In December 2010, Myriant broke ground on its 30 million pound commercial succinic acid facility in Lake Providence, Louisiana. The company’s D(-) lactic acid started production at commercial scale in June 2008 for use in polylactic acid. Myriant has agreements with Uhde GmbH for engineering, Davy Process Technology for the integration of Myriant’s succinic acid process with the Davy butanediol process for the production of bio-based butanediol, and PTT Chemical for the commercialization of Myriant’s technology in South East Asia. Myriant is headquartered in Quincy, Massachusetts. Details are available at www.myriant.com.

Contacts

Myriant Corporation
Ethel Shepard, 617-657-5248
Manager, Corporate Communications

Contacts

Myriant Corporation
Ethel Shepard, 617-657-5248
Manager, Corporate Communications